CD19 and plasma cell myeloma: To bypass single antigen escape, dual-targeted chimeric antigen receptor T-cell therapy constructs (CD19/CD22 in B-cell acute lymphoblastic leukemia and B-cell maturation antigen/CD19 in multiple myeloma) are undergoing clinical trials [16].